Dr. Jovin is an expert in interventional and non-interventional treatments for the entire spectrum of cerebrovascular disorders, including ischemic and hemorrhagic stroke, and is the leader of UPMC Stroke Institute, one of the highest volume centers in the country.
He serves as principal investigator for the recently halted REVASCAT study, a randomized trial in Spain of endovascular therapy versus medical therapy for stroke due to large artery occlusion within 8 hours, as well as principal investigator for DAWN, a multicenter, international, randomized trial of endovascular therapy versus medical therapy in the beyond 8-hour time window. He is a member of the executive/steering committee for several multicenter national and international trials, and is the site principal investigator/co-investigator for several local or multi-center clinical trials. He has published more than 150 articles in peer-reviewed journals or book chapters.
As the former UPMC Stroke Fellowship Program Director and UPMC Neurointerventional Fellowship Program Director, positions he has held for over five years, Dr. Jovin has significant experience in mentoring young neurologists or neurosurgeons who, in addition to acquiring the necessary clinical and procedural skills for successful clinical practice, have authored numerous publications in leading peer-reviewed cerebrovascular disease journals.
Dr. Jovin serves as president of the Society of Vascular and Interventional Neurology and serves on several other committees or boards of national and international societies (American Academy of Neurology, American Society of Neuroimaging,) and editorial boards of medical journals within his area of expertise (Stroke, Journal of Neuroimaging, Interventional Neurology). Dr. Jovin's clinical and research activities are focused on the care of patients with cerebrovascular disorders.